The Food and Drug Administration (FDA) on Friday approved a new therapy for treating sickle cell disease, marking the first instance of CRISPR gene editing receiving approval from federal regulators.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback